Individualizing Therapy for DME

Disease features as well as individual patient needs and preferences should drive treatment choices.

Read Article
  • Clinical Case Compendium

    Surgical case discussions from thought leaders

    Read Article
  • Maximizing Patient Outcomes in DME:

    A Discussion of Evolving, Evidence-Based Options for Clinical Practice

    Read Article


USC has a proud history of training many of the best leaders in ophthalmology. For more info:

Articles From This Issue


Examining the Systemic Safety of Anti-VEGF Agents

At a Glance • Anti-VEGF agents can enter the circulation and reduce systemic VEGF levels. • Fellow-eye effects suggest evidence of systemic effects caused by t…

A Dual-Mechanism Drug for Vitreoretinal Diseases

At a Glance • Integrins are cell surface receptors involved in angiogenesis and inflammation. • Although there are currently no anti-integrin drugs in ophthalm…


Uveitis Resource Center




Fears Of Potentially Blinding Complication From Avastin Eye Injections Are Overblown, According to Penn Study

Eye injections of the drug Avastin, used to treat retinal diseases, bring no greater risk of endopht…

NICE Recommends Ozurdex for Pseudophakic Patients with DME

The National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending …

Video Series

Contact Info

Bryn Mawr Communications LLC
1008 Upper Gulph Road, Suite 200
Wayne, PA 19087

Phone: 484-581-1800
Fax: 484-581-1818

Karen Roman

Alan B. Guralnick

About Retina Today

Retina Today is a publication that delivers the latest research and clinical developments from areas such as medical retina, retinal surgery, vitreous, diabetes, retinal imaging, posterior segment oncology and ocular trauma. Each issue provides insight from well-respected specialists on cutting-edge therapies and surgical techniques that are currently in use and on the horizon.

Website Design by Sides Media